Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
VITTAILTV Ltd.
Developing Novel Solutions To Treat Human Papilloma Virus -Related
Cancers and Prostate Cancer
Targeting Major UnmetMedical Needs
A first in class, small molecule inhibitor of a key protein (E6AP)Developed to preclinical stage prior to licensing Protected by intellectual property, including composition of matter patent(s)
Therapeutic development based on a key discovery by the founders:The Company is targeting treatments for prostate cancer and HPV-related cancers that will be:
a. b.c.
Risk minimised through:Experienced management team (drug discovery methodology, global innovators of the underlying knowhow)Experienced Board with extensive biotech start-up and development track recordIdentification of key biomarkers and the clinical nexus between E6AP and multiple cancerEstablished contracts with key service providers (SYNthesis Research, Peter Mac).Established collaborations for disease models and clinical consultationCurrently no competing IP
18%
Prostate
88%
Anus
41%
Vagina
and Vulva
44%
Oral
and Larynx
31%
Oral and
Pharynx
Penis
51%
88%
Cervix
Life expectancy HPVRelatedCancers
Cervical Cancer
Oral cavity andLarynx
Anal Cancer
Oral Cavity andPharynx Cancer
528,000
358,000
40,000
95 %
44%
88%
67.1% - all cases17.3% - metastatic disease
60.7% - all cases34.3% - metastatic disease
67% - all cases30% -metastatic
disease
GlobalNew Cases
(pa)
Percentage ofCancers
Treatable by Vittail
Vaginal and VulvarCancers
Penile Cancer #
Other Cancers
Prostate Cancer
49,000
26,000
Global NewCases (pa)
41%
51%
18%
96,000
200,000
31%
PercentageTreatable by
Vittail
5 year survival
64.5% - all cases38.5% - metastatic disease
95% - all cases73% - metastatic disease
Life expectancy 5 year survival
98.6% for all
29.8% metastatic disease
72.1% - all cases17.4% - metastatic disease
Market Size
Target Markets
Tom Peat, Ph.D. John Deadman, Ph.D.BSc in medicinal chemistry, PhD in the field ofdrug discovery.Over 25 years experience in Drug Discovery andDevelopment.Managed multidisciplinary teams globally forresearch projects and regulatory purposesunder GMP.Developed drugs under IND to Phase III clinicaltrials.Experience at management and board level inbiotech in Europe, Australasia and China.International biotech consultant with multiplepublications, grants and inventions (multiplepatents including granted patents).
Founders: Experienced Innovators
VITTAIL has an experienced clinical advisory panel including:•Prof. S. Sandhu for castration resistant prostate cancer•Prof. B. Solomon for HPV driven cancers
BS in Biochemistry and Biophysics - UC Berkeley; PhDin Molecular, Cellular & Biophysical Studies - ColumbiaUniversity. First scientist hired by SGX Pharmaceuticals, appointedDirector of Structural Biology. VP of Proteomics at OpenEye Scientific Software,established San Diego facility. Established in CSIRO fragment screening program:used by multiple international biotech andpharmaceutical companies. Helped develop inhibitors: PRMT5 sold to Merck USAin 2016 for US$500M, other inhibitors sold to Pfizer in2018 for US$490M.Experienced in solving >1000 protein structures,multiple publications & co-founder of MecRX & Vittail.
PhD - Walter and Eliza Hall, discovered Bmi1; postdoctoral research at the WeizmannInstitute; Major discovery of the degradationof p53 by Mdm2.World-leading researcher in tumoursuppression with a focus on cancer biology ofthe ubiquitin proteasome system.Led 2 large consortia (Europe and Australiawith over $27m in research funding),supervised over 80 students/research staff.Multiple awards/fellowships (includingNHMRC and the Victorian Endowment forScience Knowledge and Innovation).
Ygal Haupt, Ph.D.
SAB
Fragment-Based Drug Design (FBDD) screening processPartner Organisations’ Roles
Biological assaysAlphaScreen activity/counter-
screen/selectivity)ubiquitination, pre-clinical
mouse models
Medicinal chemistryFragment optimisation
physicochemical optimisation(ADMET/ “drug likeness”)X-ray crystallography
Fragments and ligands usingAustralian Synchrotron
Fragment Libraries
Biophysical assaysSPR and STD NMR
Preclinical lead drug
CSIRO
CSIROBio21
SynchrotronCSIRO
PeterMac
SYNthesisCDCO
VITTAIL
The Target: E6-AssociatedProtein (E6AP)
E6AP is critical for high-risk HPV-related and prostate cancers
E6AP ordinarily regulates the expression of three key tumour
suppressors in the body - p53, PML and p27.
In cancers E6AP is ‘over activated’ causing the destruction of
tumour suppressors.
VITTAIL’s therapeutic approach is to inhibit E6AP to restore the
body’s tumour suppressive capacity.
E6AP promotes cancer by degrading the patient’s tumoursuppressing protein (PML) in prostate cancer
Prostate
20
40
60
80
100
0
Lymphom
a
Germ C
ellLung
Breast
Colon
CNS
Complete
Loss
Partial
Loss
Major cancers in which thekey target of E6AP is lost.These are relevant cancersfor VITTAILS’s noveltherapeutic approach
Targeting E6AP inhibits prostate cancerprolonging the life of experimental mice.
The growth of human prostate cancer is significantly inhibited by depletingE6AP in experimental models. Depletion of E6AP restores the body’s anti-canceractivities.
With
E6AP
Without
E6AP
Timeline for Drug Development
Capital-efficient structure & key discovery partnership with CSIRO provides a rapid path
to a commercialisation event
Assay Platform
Establishment
Fragment
Screen
Multiple
Hits/Early Leads
IdentifiedLicensing
event
Compound
Optimization
Test Compound
as E6AP
inhibitor in
cancer models
Negotiate
Licensing
transaction/
M&A
2 0 2 42 0 2 0 - 2 1 2 0 2 1 - 2 0 2 2 2 0 2 3
Proof
of concept
data
Offer Summary
Amount to be Raised
Offer Price PerPrefence Share
Number of New PreferenceShares Being Offered
Valuation of ViITTAIL pre-raising
$1.5 Million
(with the ability to accept over subscriptions)
Total Number of Shares After Raising
(including Ordinary Shares and
Preference Shares)
Indicative Capitalisation ofCompany After Raising
$1
1.5 Million
(with the ability to accept over subscriptions)
$1.5 Million
2 Million Preference Shares
1 Million Ordinary Shares
Additional shares will also be issued if there are any
oversubscriptions
$3 Million